a-t 2016; 47: 23

Urinary incontinence due to safinamide (XADAGO)?: Due to fluctuations in the effect of her PARKINSON's medication, a 78-year-old women is additionally taking the new selective monoamine oxidase B inhibitor safinamide (XADAGO; see a t 2015; 46: 63-5). Shortly after this the patient developed urinary incontinence that she had not had before and that continued over the following days on which she was taking the medication. It only improved after the dose of safinamide was halved (NETZWERK Report 16.947). According to the Summary of Product Characteristics (SPC) (1), disorders of bladder function such as a micturation urgency, polyuria and nycturia may occur in patients taking safinamide. The database of the Federal Institute for Drugs and Medical Devices (BfArM) (2) lists a total of twelve side effect reports on safinamide including one report each of polyuria and nycturia with an urge to urinate, but there are no reports on urinary incontinence. In light of the small amount of experience with safinamide, please be vigilant and inform our NETZWERK DER GEGENSEITIGEN INFORMATION (Network of mutual information) if patients being treated with safinamide complain of incontinence.